These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26310546)

  • 1. Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder.
    Ciftci S; Ozkurkcugil C; Yilmaz H; Ustuner M; Yavuz U; Yuksekkaya M; Cekmen MB
    Int Urogynecol J; 2016 Feb; 27(2):275-80. PubMed ID: 26310546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
    Liu HT; Lin H; Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary nerve growth factor in children with overactive bladder: a promising, noninvasive and objective biomarker.
    Oktar T; Kocak T; Oner-Iyidogan Y; Erdem S; Seyithanoglu M; Ziylan O; Kocak H
    J Pediatr Urol; 2013 Oct; 9(5):617-21. PubMed ID: 22789557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
    Kim SR; Moon YJ; Kim SK; Bai SW
    Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
    Liu HT; Chancellor MB; Kuo HC
    BJU Int; 2009 Jun; 103(12):1668-72. PubMed ID: 19220267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solifenacin and Tamsulosin Combination Therapy Decreases Urine Nerve Growth Factor/Creatinine Levels in Men.
    Chan R; Munoz A; Wenker EP; Whipple M; Miles B; Boone TB
    Urology; 2016 May; 91():150-3. PubMed ID: 26829718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary Nerve Growth Factor Can Predict Therapeutic Efficacy in Children With Overactive Bladder.
    Fukui S; Aoki K; Morizawa Y; Miyake M; Fujimoto K
    Urology; 2017 May; 103():214-217. PubMed ID: 28161379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment.
    Liu HT; Kuo HC
    Urology; 2008 Jul; 72(1):104-8; discussion 108. PubMed ID: 18400272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder.
    Hsiao SM; Chang TC; Chen CH; Wu WY; Lin HH
    Menopause; 2017 Jan; 24(1):100-104. PubMed ID: 27648660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention.
    Liu HT; Kuo HC
    Neurourol Urodyn; 2009; 28(1):78-81. PubMed ID: 19089891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of biomarkers in the diagnosis and treatment of overactive bladder: Can we predict the patients who will be resistant to treatment?
    Alkis O; Zumrutbas AE; Toktas C; Aybek H; Aybek Z
    Neurourol Urodyn; 2017 Feb; 36(2):390-393. PubMed ID: 26661444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial.
    Aydoğmuş Y; Sunay M; Arslan H; Aydın A; Adiloğlu AK; Şahin H
    Urol Int; 2014; 93(4):437-43. PubMed ID: 25033919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
    Liu HT; Chancellor MB; Kuo HC
    Eur Urol; 2009 Oct; 56(4):700-6. PubMed ID: 18472208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
    Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
    BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder.
    Wang LW; Han XM; Chen CH; Ma Y; Hai B
    Int Urol Nephrol; 2014 Feb; 46(2):341-7. PubMed ID: 23982767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis.
    Sheng W; Zhang H; Ruth KH
    Neurourol Urodyn; 2017 Sep; 36(7):1703-1710. PubMed ID: 28102552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could urinary nerve growth factor and bladder wall thickness predict the treatment outcome of children with overactive bladder?
    Huseynov A; Telli O; Haciyev P; Okutucu TM; Akinci A; Ozkidik M; Erguder I; Fitoz S; Burgu B; Soygur T
    Int Braz J Urol; 2022; 48(3):553-560. PubMed ID: 35373950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome.
    Beta A; Giannouli A; Rizos D; Mantzou A; Deligeoroglou E; Bakas P
    Int Urogynecol J; 2024 Jun; 35(6):1317-1322. PubMed ID: 38761233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder.
    Yokoyama T; Kumon H; Nagai A
    Neurourol Urodyn; 2008; 27(5):417-20. PubMed ID: 17924444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.